|
Chongqing Lummy Pharmaceutical Co., Ltd. (300006.sz) Avaliação DCF
CN | Healthcare | Drug Manufacturers - General | SHZ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ) Bundle
Obtenha informações sobre a análise de avaliação de Chongqing Lummy Pharmaceutical Co., Ltd. (300006SZ) com nossa sofisticada calculadora DCF! Pré -carregado com dados reais (300006SZ), este modelo do Excel permite ajustar as previsões e suposições para determinar com precisão o valor intrínseco da Chongqing Lummy Pharmaceutical Co., Ltd.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,859.0 | 1,583.5 | 1,225.2 | 884.6 | 895.6 | 752.3 | 631.9 | 530.8 | 445.9 | 374.5 |
| Revenue Growth, % | 0 | -14.82 | -22.63 | -27.8 | 1.24 | -16 | -16 | -16 | -16 | -16 |
| EBITDA | 34.5 | -148.6 | -1.2 | 19.5 | 116.5 | 11.4 | 9.6 | 8.1 | 6.8 | 5.7 |
| EBITDA, % | 1.86 | -9.38 | -0.09741654 | 2.2 | 13.01 | 1.52 | 1.52 | 1.52 | 1.52 | 1.52 |
| Depreciation | 109.5 | 110.4 | 75.6 | 78.2 | 75.4 | 54.6 | 45.9 | 38.5 | 32.4 | 27.2 |
| Depreciation, % | 5.89 | 6.97 | 6.17 | 8.84 | 8.42 | 7.26 | 7.26 | 7.26 | 7.26 | 7.26 |
| EBIT | -75.0 | -258.9 | -76.8 | -58.7 | 41.1 | -43.2 | -36.3 | -30.5 | -25.6 | -21.5 |
| EBIT, % | -4.03 | -16.35 | -6.27 | -6.64 | 4.59 | -5.74 | -5.74 | -5.74 | -5.74 | -5.74 |
| Total Cash | 436.7 | 544.9 | 559.4 | 846.3 | 836.4 | 440.3 | 369.8 | 310.7 | 260.9 | 219.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 686.2 | 533.2 | 445.4 | 348.4 | 607.9 | 322.3 | 270.7 | 227.4 | 191.0 | 160.4 |
| Account Receivables, % | 36.91 | 33.67 | 36.35 | 39.38 | 67.88 | 42.84 | 42.84 | 42.84 | 42.84 | 42.84 |
| Inventories | 316.7 | 296.7 | 157.8 | 202.4 | 171.0 | 136.3 | 114.5 | 96.2 | 80.8 | 67.9 |
| Inventories, % | 17.04 | 18.73 | 12.88 | 22.88 | 19.09 | 18.12 | 18.12 | 18.12 | 18.12 | 18.12 |
| Accounts Payable | 93.7 | 69.4 | 34.3 | 49.6 | 37.9 | 33.2 | 27.9 | 23.4 | 19.7 | 16.5 |
| Accounts Payable, % | 5.04 | 4.38 | 2.8 | 5.61 | 4.23 | 4.41 | 4.41 | 4.41 | 4.41 | 4.41 |
| Capital Expenditure | -63.1 | -43.6 | -38.7 | -68.2 | -59.3 | -35.6 | -29.9 | -25.1 | -21.1 | -17.7 |
| Capital Expenditure, % | -3.39 | -2.75 | -3.15 | -7.71 | -6.62 | -4.73 | -4.73 | -4.73 | -4.73 | -4.73 |
| Tax Rate, % | 348.37 | 348.37 | 348.37 | 348.37 | 348.37 | 348.37 | 348.37 | 348.37 | 348.37 | 348.37 |
| EBITAT | -68.6 | -246.3 | -72.8 | -53.6 | -102.0 | -32.2 | -27.0 | -22.7 | -19.1 | -16.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -931.4 | -30.6 | 155.6 | 24.1 | -325.8 | 302.5 | 57.0 | 47.9 | 40.2 | 33.8 |
| WACC, % | 6.6 | 6.61 | 6.61 | 6.6 | 6.33 | 6.55 | 6.55 | 6.55 | 6.55 | 6.55 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 429.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 34 | |||||||||
| Terminal Value | 758 | |||||||||
| Present Terminal Value | 552 | |||||||||
| Enterprise Value | 981 | |||||||||
| Net Debt | -562 | |||||||||
| Equity Value | 1,544 | |||||||||
| Diluted Shares Outstanding, MM | 1,050 | |||||||||
| Equity Value Per Share | 1.47 |
What You Will Receive
- Customizable Excel Template: A fully editable Excel-based DCF Calculator featuring pre-filled financials for Lummy Pharmaceutical Co., Ltd. (300006SZ).
- Comprehensive Data: Access to historical data along with forward-looking projections (highlighted in the yellow cells).
- Adjustable Projections: Modify key assumptions such as revenue growth, EBITDA %, and WACC at your discretion.
- Instant Calculations: Quickly observe how your inputs affect the valuation of Lummy Pharmaceutical Co., Ltd. (300006SZ).
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive Design: Organized for clarity and straightforward use, accompanied by step-by-step guidance.
Key Features
- 🔍 Real-Life (300006SZ) Financials: Pre-filled historical and projected data for Chongqing Lummy Pharmaceutical Co., Ltd.
- ✏️ Fully Customizable Inputs: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Integrated formulas compute Chongqing Lummy's intrinsic value utilizing the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize the company's valuation immediately after making adjustments.
- Scenario Analysis: Evaluate and compare various financial outcomes side-by-side based on different assumptions.
How It Operates
- 1. Access the Template: Download and open the Excel file containing Chongqing Lummy Pharmaceutical Co., Ltd.'s (300006SZ) preloaded data.
- 2. Adjust Assumptions: Modify essential inputs such as growth rates, WACC, and capital expenditures.
- 3. Instant Results: The DCF model automatically computes intrinsic value and NPV in real-time.
- 4. Explore Scenarios: Evaluate various forecasts to assess different valuation outcomes.
- 5. Make Informed Decisions: Present professional valuation insights to confidently support your choices.
Why Opt for Chongqing Lummy Pharmaceutical's Calculator?
- All-in-One Solution: Combines DCF, WACC, and financial ratio analyses for comprehensive assessments.
- Flexible Inputs: Modify the highlighted cells to explore different financial scenarios.
- In-depth Analysis: Automatically calculates the intrinsic value and Net Present Value of Chongqing Lummy Pharmaceutical (300006SZ).
- Loaded with Data: Comes equipped with historical and forecasted data for reliable baseline evaluations.
- Designed for Professionals: Perfect for financial analysts, investors, and business consultants seeking quality insights.
Who Is This Product For?
- Individual Investors: Gain insights to make educated decisions about investing in Chongqing Lummy Pharmaceutical Co., Ltd. (300006SZ).
- Financial Analysts: Enhance valuation processes with comprehensive financial models tailored for the pharmaceutical sector.
- Consultants: Provide clients with accurate valuation assessments and market insights related to Chongqing Lummy Pharmaceutical Co., Ltd. (300006SZ).
- Business Owners: Learn how major players like Chongqing Lummy Pharmaceutical Co., Ltd. (300006SZ) are valued to inform your business strategy.
- Finance Students: Explore valuation methodologies using real-world examples from the pharmaceutical industry.
Overview of the Template's Features
- In-Depth DCF Model: Editable template featuring comprehensive valuation calculations.
- Relevant Data: Chongqing Lummy Pharmaceutical Co., Ltd.'s historical and projected financials preloaded for your analysis.
- Adjustable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for assessing profitability, efficiency, and leverage.
- Dashboard with Visual Outputs: Dynamic charts and tables for presenting clear, actionable insights.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.